Condition, prevalence, incidence and trend direction — lower extremity lymphedema

1. Summary

No single study measures US population prevalence or incidence for lower-extremity lymphedema specifically; every retrievable quantity is a proxy, a subtype share, or a rate confined to one etiology. Three national-scale proxies exist for lymphedema overall (not limb-specific) and all three move in the same direction: hospitalization-coded prevalence rose from 0.40% to 0.50% of US hospitalizations between 2016 and 2020, and a separate vital-registration analysis reports proportionate mortality "increasing for the past two decades." Where incidence is directly measured, it is concentrated in cancer-treatment-related secondary lower-extremity lymphedema, where a US NIH-funded multicenter cohort and an independent global meta-analysis both put post-lymphadenectomy incidence in the 28–43% range depending on cancer site and lymph-node surgery extent. No source in this pass separates primary (congenital) from secondary lower-extremity lymphedema at a population level, and no source breaks the two national proxy studies out by anatomic site.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

Condition

Lymphedema is chronic lymphatic-drainage impairment producing progressive limb swelling; below the knee, the two recognized routes into the condition that this domain's dossier already distinguishes are primary (congenital/idiopathic) and secondary (post-surgical, post-radiation, or venous-disease-associated) disease. One retrieved position statement states that "phlebolymphedema, a subtype linked to chronic venous insufficiency (CVI), accounts for 41.8% of lower extremity lymphedema cases and contributes to an economic burden exceeding $1 billion over 5 years" [3] [single-source] — the denominator study and population behind that percentage are not given in the abstract retrieved here, and it is the only source in this pass reporting a lower-extremity-specific subtype share at all.

Population-level prevalence — three proxies, no direct estimate

Verbatim: "Lymphedema was present in 0.45% (n = 792,475) of all hospitalizations; with prevalence increasing from 0.40% in 2016 to 0.50% in 2020." [1] [single-source]

Verbatim: "In the US, the estimated prevalence of lymphedema was 2.7 per 10,000 deaths for women and 1.5 per 10,000 deaths for men... The estimated prevalence of lymphedema is 2- to 3-times higher than previously thought and has been increasing for the past two decades." [2] [single-source]

Neither [1] nor [2] is limb-specific — both count lymphedema of any site, coded from an inpatient discharge or a cause-of-death record, and neither abstract reports a lower-extremity breakout. [1] captures only the hospitalized, most-severe end of the disease; [2] is a proportionate-mortality proxy, which measures how often lymphedema is coded as contributing to death, not how many people live with it — its own authors frame their 2- to 3-fold upward revision as evidence the field previously lacked an agreed estimate. Both point the same direction (rising), but neither is a population-prevalence figure and neither isolates the lower extremity.

Incidence — concentrated in cancer-treatment-related secondary lower-extremity lymphedema

The only directly measured incidence figures located in this pass are for secondary lower-extremity lymphedema following gynecologic-cancer lymph node surgery — a US NIH-funded multicenter cohort and an independent global meta-analysis, neither citing the other's figure:

Verbatim: "The incidence of LVC ≥10% was 34% (n = 247), 35% (n = 48), and 43% (n = 18), respectively. The peak incidence of lymphedema was at the 4-6 week assessment." [4] [single-source]

Verbatim: "Twenty-seven studies met the inclusion criteria for the assessment of lymphedema incidence with a pooled estimate of 28.8% (95% confidence interval (CI) 22.1-35.5)... The incidence of LLL was increased by approximately 5-fold in women who underwent inguinofemoral lymph node dissection compared to those who underwent sentinel lymph node biopsy." [5] [single-source]

Verbatim: "Limb swelling was reported in 4.1% of patients, while only one patient (1.0%) met the criteria for self-reported mild lymphedema. No clinical signs of inguinal lymphedema were detected." [6] [single-source]

Verbatim: "ILR reduced the risk of LEL by 30.3 per 100 patients treated compared with no ILR (risk difference, -30.3%; 95% CI, -46.5% to -14%; P<.001)." [7] [single-source]

Read together, [4]–[7] agree on direction and rough order of magnitude — roughly a quarter to a third of women undergoing inguinal/pelvic lymph node dissection for a gynecologic malignancy develop measurable lower-extremity lymphedema, and both technique changes examined (a less-invasive nodal-mapping approach [6] and a preventive microsurgical reconstruction [7]) report substantially lower incidence than the older-technique baseline in [4]/[5]. None of these four sources is a US general-population figure; [4] is the only one confirmed US-sited (GOG is a US NIH-affiliated cooperative group, and the abstract carries a "Research Support, N.I.H., Extramural" indexing tag), [5] pools multiple countries not individually identified in the retrieved abstract, and [6]/[7] do not state a country for the underlying patient cohorts.

Trend direction

The two national-scale US proxies in the prevalence table above both point upward over comparable windows: hospitalization-coded lymphedema prevalence rose year-over-year from 2016 to 2020 [1], and vital-registration proportionate mortality is described by its own authors as "increasing for the past two decades" [2]. No source in this pass reports a downward or flat trend for any lymphedema prevalence proxy. On the incidence side, no source directly measures a time trend (all four incidence figures in the table above are single-window cohort or pooled-meta-analysis estimates, not a series); the two technique-comparison findings ([6], [7]) show that incidence under contemporary lower-morbidity surgical technique is lower than the older-technique cohort baseline in [4]/[5], which describes a shift in the composition of incidence by technique rather than a population-wide trend over time.

4. Sources

[1] Epidemiological Study of Lymphedema Prevalence and Comorbidities in Hospitalized Patients in the United States — Journal of Clinical Medicine (published 2025; accessed 2026-09-01). PMID 41303192 — https://pubmed.ncbi.nlm.nih.gov/41303192/ [peer-reviewed] [2] Prevalence of Lymphedema Using Large Data Sets: An Epidemiological Analysis in the United States and in Italy — Lymphology (published 2023; accessed 2026-09-01). PMID 39207410 — https://pubmed.ncbi.nlm.nih.gov/39207410/ [peer-reviewed] [3] Non-pneumatic compression and its clinical utility in management of lymphedema. A position statement endorsed by the American Venous Forum and the American Venous and Lymphatic Society — Journal of Vascular Surgery: Venous and Lymphatic Disorders (published 2026; accessed 2026-09-01). PMID 41271100 — https://pubmed.ncbi.nlm.nih.gov/41271100/ [guideline] [4] GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients — Gynecologic Oncology (published 2020; accessed 2026-09-01). PMID 31837831 — https://pubmed.ncbi.nlm.nih.gov/31837831/ [peer-reviewed] [5] Incidence of lower limb lymphedema after vulvar cancer: A systematic review and meta-analysis — Medicine (published 2017-11; accessed 2026-09-01). PMID 29145314 — https://pubmed.ncbi.nlm.nih.gov/29145314/ [peer-reviewed] [6] Minimizing Lymphatic Morbidity: Incidence of Lower Extremity Lymphedema After vNOTES-Assisted Sentinel Node Mapping in Endometrial Cancer — Current Oncology (published 2026; accessed 2026-09-01). PMID 42041727 — https://pubmed.ncbi.nlm.nih.gov/42041727/ [peer-reviewed] [7] Microsurgical treatment of lower extremity lymphedema: An umbrella systematic review supporting the American Venous Forum and the American Vein and Lymphatic Society clinical practice guidelines on management of lymphedema — Journal of Vascular Surgery: Venous and Lymphatic Disorders (published 2026; accessed 2026-09-01). PMID 42208734 — https://pubmed.ncbi.nlm.nih.gov/42208734/ [peer-reviewed]

5. Sourcing & Gaps

Well established: Nothing in this report rests on two or more independent, non-affiliated primary sources reporting the same quantity — the closest is the shared upward direction of [1] and [2], which measure different things (hospitalization coding and mortality coding respectively) and are reported separately in section 3 rather than combined into a plain statement, per the marker rule for anything short of true corroboration.

Thin: every substantive quantity in section 3 is [single-source]: hospitalization prevalence and its 2016–2020 trend [1]; mortality-proportionate prevalence and its two-decade trend [2]; the 41.8% phlebolymphedema share, additionally directional as a professional-society position statement [3]; the GOG 244 by-cancer-site incidence figures [4]; the pooled vulvar cancer meta-analysis incidence [5]; the vNOTES low-incidence cohort [6]; and the ILR risk reduction figure, itself drawn from an umbrella review of other reviews rather than a single primary trial [7].

Rescoped from class 3: none. Every question this report attempted is a class 1 or class 2 question (a registry-style vital-statistics/discharge-data proxy, or a published measured rate) — no stakeholder-future question arose within the epidemiology scope, so no rescoping was needed.

Out of scope: CDC WONDER queried directly, SEER, and any non-PubMed federal surveillance system, per the scope statement above — this report relied on PubMed abstracts of studies that themselves used such datasets (e.g., [1] uses the Nationwide Inpatient Sample, [2] uses US vital registration data), not on a direct connector or fetch against those systems. HCPCS/CFR reimbursement material is out of scope for this section; it belongs to (and is already covered by) the domain's reimbursement section.

Not searched vs. not found: A US population-prevalence or incidence figure specific to lower-extremity lymphedema (as opposed to lymphedema of any site) was searched for across multiple query forms in this pass and not found — consistent with the same conclusion the domain dossier already reached. A dedicated incidence or birth-prevalence figure for primary (congenital) lower-extremity lymphedema was searched for and not found; the retrieved results were case reports, a Turner-syndrome cohort, and lymphatic-filariasis studies, none of which gave a US primary-lymphedema incidence or prevalence figure. A direct incidence or progression-rate figure for chronic-venous-insufficiency-associated phlebolymphedema (as distinct from the 41.8% subtype-share figure in [3]) was searched for and returned zero PubMed records for the query form used — a real null, not an unsearched gap, though a differently worded query might still surface one. Demographic concentration (age, race, region) specific to lower-extremity lymphedema was not searched in this pass; it remains an open item already flagged in the domain dossier.

[inference] The rising gynecologic-malignancy incidence noted in an unrelated retrieved abstract's background section ("the incidence of gynecological malignancies continues to increase worldwide" — not independently verified by this report, and not carried into section 3 as a finding) would, if true and combined with lymph-node dissection remaining part of standard surgical staging, plausibly add upward pressure to secondary lower-extremity lymphedema incidence over time. No source located in this pass measures that causal chain directly, so this synthesis stays here rather than in section 3.

6. Claim Candidates